Motley Fool  Jun 20  Comment 
Based on a trial of Eli Lilly's SGLT-2 inhibitor, Jardiance, the treatment may significantly reduce heart attacks and strokes for diabetes patients. But it's by no means assured that Lilly will be the big beneficiary of the news.
Motley Fool  Jun 15  Comment 
It's a showdown between the healthcare conglomerate and the diabetes pioneer.
newratings.com  Jun 9  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte Corp. (INCY) announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology in London. The findings demonstrate...
Benzinga  Jun 8  Comment 
Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3 studies—UNCOVER-1, UNCOVER-2 and UNCOVER-3—that demonstrated the efficacy and safety of...
Benzinga  Jun 7  Comment 
Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from baricitinib's phase 3 global studies will be presented, along with other...
Motley Fool  Jun 5  Comment 
Both big pharmas are returning to top-line growth, but which is the better buy?
Benzinga  Jun 3  Comment 
Morgan Stanley said the negative news on Alimta is disappointing for Eli Lilly and Co (NYSE: LLY) as the patent was upheld in District Court last year. The PTAB instituted a review of Alimta's '209 patent. A final ruling is expected within a...
Benzinga  May 31  Comment 
Eli Lilly and Company (NYSE: LLY) revealed Tuesday that the Food and Drug Administration has approved its Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults....
Forbes  May 27  Comment 
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in HanesBrands Inc (NYSE: HBI), where a total volume of 20,828 contracts has been traded thus far today, a contract volume which is...

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki